Corey M Gill1, Joshua Loewenstern2, John W Rutland2, Hanane Arib3, Margaret Pain2, Melissa Umphlett4, Yayoi Kinoshita4, Russell B McBride4,5, Joshua Bederson2, Michael Donovan4, Robert Sebra3,6, Mary Fowkes4, Raj K Shrivastava2. 1. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. corey.gill@icahn.mssm.edu. 2. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. 3. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5. The Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 6. Sema4, A Mount Sinai venture, Stamford, CT, USA.
Abstract
PURPOSE: Meningiomas are the most common primary central nervous system tumor. Emerging data supports that higher mutational burden portends worse clinical outcomes in meningiomas. However, there is a lack of imaging biomarkers that are associated with tumor genomics in meningiomas. METHODS: We performed next-generation targeted sequencing in a cohort of 75 primary meningiomas and assessed preoperative imaging for tumor volume and peritumoral brain edema (PTBE). An Edema Index was calculated. RESULTS: Meningiomas that were high grade (WHO grade II or grade III) had significantly larger tumor volume and were more likely to present with PTBE. Moreover, PTBE was associated with brain invasion on histopathology and reduced overall survival. There was a direct association between Edema Index and mutational burden. For every one increase in Edema Index, the number of single nucleotide variants increased by 1.09-fold (95% CI: 1.02, 1.2) (P = 0.01). CONCLUSION: These data support that Edema Index may serve as a novel imaging biomarker that can inform underlying mutational burden in patients with meningiomas.
PURPOSE:Meningiomas are the most common primary central nervous system tumor. Emerging data supports that higher mutational burden portends worse clinical outcomes in meningiomas. However, there is a lack of imaging biomarkers that are associated with tumor genomics in meningiomas. METHODS: We performed next-generation targeted sequencing in a cohort of 75 primary meningiomas and assessed preoperative imaging for tumor volume and peritumoral brain edema (PTBE). An Edema Index was calculated. RESULTS:Meningiomas that were high grade (WHO grade II or grade III) had significantly larger tumor volume and were more likely to present with PTBE. Moreover, PTBE was associated with brain invasion on histopathology and reduced overall survival. There was a direct association between Edema Index and mutational burden. For every one increase in Edema Index, the number of single nucleotide variants increased by 1.09-fold (95% CI: 1.02, 1.2) (P = 0.01). CONCLUSION: These data support that Edema Index may serve as a novel imaging biomarker that can inform underlying mutational burden in patients with meningiomas.
Entities:
Keywords:
Biomarker; Central nervous system; Edema; Imaging; Meningioma; Sequencing
Authors: Dorothee Cäcilia Spille; Peter B Sporns; Katharina Heß; Walter Stummer; Benjamin Brokinkel Journal: World Neurosurg Date: 2019-05-10 Impact factor: 2.104
Authors: Raymond Y Huang; Wenya Linda Bi; Brent Griffith; Timothy J Kaufmann; Christian la Fougère; Nils Ole Schmidt; Jöerg C Tonn; Michael A Vogelbaum; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Ian F Dunn Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300
Authors: Thibaud P Coroller; Wenya Linda Bi; Elizabeth Huynh; Malak Abedalthagafi; Ayal A Aizer; Noah F Greenwald; Chintan Parmar; Vivek Narayan; Winona W Wu; Samuel Miranda de Moura; Saksham Gupta; Rameen Beroukhim; Patrick Y Wen; Ossama Al-Mefty; Ian F Dunn; Sandro Santagata; Brian M Alexander; Raymond Y Huang; Hugo J W L Aerts Journal: PLoS One Date: 2017-11-16 Impact factor: 3.240
Authors: David van Nieuwenhuizen; K Mariam Slot; Martin Klein; Dagmar Verbaan; Esther Sanchez Aliaga; Jan J Heimans; W Peter Vandertop; Saskia M Peerdeman; Jaap C Reijneveld Journal: Acta Neurochir (Wien) Date: 2019-02-13 Impact factor: 2.216